Reviewing Orchestra BioMed (NASDAQ:OBIO) and Drägerwerk AG & Co. KGaA (OTCMKTS:DGWPF)

Drägerwerk AG & Co. KGaA (OTCMKTS:DGWPF) and Orchestra BioMed (NASDAQ:OBIO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

13.9% of Drägerwerk AG & Co. KGaA shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Drägerwerk AG & Co. KGaA and Orchestra BioMed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drägerwerk AG & Co. KGaA	0	0	0	0	0.00
Orchestra BioMed	1	1	5	0	2.57

Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 230.10%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Drägerwerk AG & Co. KGaA.

Profitability

This table compares Drägerwerk AG & Co. KGaA and Orchestra BioMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Drägerwerk AG & Co. KGaA	N/A	N/A	N/A
Orchestra BioMed	-166.96%	-157.46%	-60.18%

Valuation & Earnings

This table compares Drägerwerk AG & Co. KGaA and Orchestra BioMed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drägerwerk AG & Co. KGaA	N/A	N/A	N/A	$5.51	16.88
Orchestra BioMed	$32.72 million	7.54	-$52.70 million	($0.97)	-4.25

Drägerwerk AG & Co. KGaA has higher earnings, but lower revenue than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Drägerwerk AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Summary

Orchestra BioMed beats Drägerwerk AG & Co. KGaA on 6 of the 11 factors compared between the two stocks.

About Drägerwerk AG & Co. KGaA

Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. Its products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, hospitable consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, system products, and other services. The company's product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, and alcohol and drug testing devices. In addition, it offers various training and services, as well as fire training facilities for firefighters. The company was founded in 1889 and is headquartered in Lübeck, Germany. Drägerwerk AG & Co. KGaA operates as a subsidiary of Stefan DrÄGer Gmbh.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.